Muscular Dystrophy in the Japanese Spitz: an Inversion Disrupts the DMD and RPGR Genes
Overview
Affiliations
An X-linked muscular dystrophy, with deficiency of full-length dystrophin and expression of a low molecular weight dystrophin-related protein, has been described in Japanese Spitz dogs. The aim of this study was to identify the causative mutation and develop a specific test to identify affected cases and carrier animals. Gene expression studies in skeletal muscle of an affected animal indicated aberrant expression of the Duchenne muscular dystrophy (dystrophin) gene and an anomaly in intron 19 of the gene. Genome-walking experiments revealed an inversion that interrupts two genes on the X chromosome, the Duchenne muscular dystrophy gene and the retinitis pigmentosa GTPase regulator gene. All clinically affected dogs and obligate carriers that were tested had the mutant chromosome, and it is concluded that the inversion is the causative mutation for X-linked muscular dystrophy in the Japanese Spitz breed. A PCR assay that amplifies mutant and wild-type alleles was developed and proved capable of identifying affected and carrier individuals. Unexpectedly, a 7-year-old male animal, which had not previously come to clinical attention, was shown to possess the mutant allele and to have a relatively mild form of the disease. This observation indicates phenotypic heterogeneity in Japanese Spitz muscular dystrophy, a feature described previously in humans and Golden Retrievers. With the availability of a simple, fast and accurate test for Japanese Spitz muscular dystrophy, detection of carrier animals and selected breeding should help eliminate the mutation from the breed.
Current Classification of Canine Muscular Dystrophies and Identification of New Variants.
Shelton G, Minor K, Friedenberg S, Cullen J, Guo L, Mickelson J Genes (Basel). 2023; 14(8).
PMID: 37628610 PMC: 10454810. DOI: 10.3390/genes14081557.
CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein.
Egorova T, Polikarpova A, Vassilieva S, Dzhenkova M, Savchenko I, Velyaev O Mol Ther Methods Clin Dev. 2023; 30:161-180.
PMID: 37457303 PMC: 10339130. DOI: 10.1016/j.omtm.2023.06.006.
CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.
Chey Y, Arudkumar J, Aartsma-Rus A, Adikusuma F, Thomas P WIREs Mech Dis. 2022; 15(1):e1580.
PMID: 35909075 PMC: 10078488. DOI: 10.1002/wsbm.1580.
CRISPR/Cas correction of muscular dystrophies.
Zhang Y, Nishiyama T, Olson E, Bassel-Duby R Exp Cell Res. 2021; 408(1):112844.
PMID: 34571006 PMC: 8530959. DOI: 10.1016/j.yexcr.2021.112844.
Sarcoglycan A mutation in miniature dachshund dogs causes limb-girdle muscular dystrophy 2D.
Mickelson J, Minor K, Guo L, Friedenberg S, Cullen J, Ciavarella A Skelet Muscle. 2021; 11(1):2.
PMID: 33407862 PMC: 7789357. DOI: 10.1186/s13395-020-00257-y.